Philip J. Mease, Eros Papademetriou, Ravi Potluri, Ekta Agarwal, Joseph C. Cappelleri, You-Li Ling
{"title":"托法替尼治疗银屑病关节炎患者的依从性、持续性、医疗资源使用和成本：来自两个美国索赔数据库的数据。","authors":"Philip J. Mease, Eros Papademetriou, Ravi Potluri, Ekta Agarwal, Joseph C. Cappelleri, You-Li Ling","doi":"10.1007/s12325-024-02904-y","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Associations between increased functional disability and higher healthcare resource utilization (HCRU) and costs were reported in patients with psoriatic arthritis (PsA). We assessed characteristics/outcomes of patients with PsA receiving tofacitinib monotherapy vs combination therapy with conventional synthetic disease-modifying antirheumatic drugs.</p><h3>Methods</h3><p>Claims data from Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart (OC) and Merative™ MarketScan<sup>®</sup> (MS) databases between December 2017 and February 2020 were analyzed. Outcomes assessed were adherence/persistence by therapy type (monotherapy/combination therapy); HCRU/costs (per patient per month) by periods on-treatment (sum time on tofacitinib) and off-treatment (sum time off tofacitinib [gap of > 60 days]) plus therapy type.</p><h3>Results</h3><p>This analysis included 274 and 395 tofacitinib-treated patients in OC (70.4% female, mean age 54.4 years) and MS (68.9% female, mean age 51.4 years), respectively. Percentages of patients with a proportion of days covered ≥ 0.8 at 12 months for monotherapy vs combination therapy were OC, 44.5% vs 53.8%; MS, 36.4% vs 45.7%. Generally similar trends were seen over 24 months and for medication possession ratio ≥ 0.8. Median (95% confidence interval) times to treatment discontinuation for monotherapy vs combination therapy were OC, 10.1 (7.4–11.8) vs 16.7 (8.3–26.6) months; MS, 6.9 (5.6–9.4) vs 11.0 (6.1–13.9) months. During off-treatment vs on-treatment periods, numerical decreases were observed for all-cause (OC, $5383 vs $6149; MS, $4145 vs $5180) and PsA-related costs (OC, $3237 vs $4515; MS, $2703 vs $3907) regardless of therapy type. During off-treatment vs on-treatment periods, numerical increases in outpatient visits for all-cause (OC, 2.37 vs 2.05; MS, 2.15 vs 1.99) and PsA-related visits (OC, 0.60 vs 0.46; MS, 0.47 vs 0.44) were observed, and PsA-related medications numerically decreased (OC, 1.21 vs 1.53; MS, 1.05 vs 1.48).</p><h3>Conclusion</h3><p>In this USA-based claims analysis, tofacitinib adherence was numerically lower for patients with PsA receiving monotherapy vs combination therapy. Costs numerically decreased off-treatment vs on-treatment, irrespective of therapy type, driven by lower medication costs.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 10","pages":"3850 - 3867"},"PeriodicalIF":3.4000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399223/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases\",\"authors\":\"Philip J. Mease, Eros Papademetriou, Ravi Potluri, Ekta Agarwal, Joseph C. Cappelleri, You-Li Ling\",\"doi\":\"10.1007/s12325-024-02904-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Associations between increased functional disability and higher healthcare resource utilization (HCRU) and costs were reported in patients with psoriatic arthritis (PsA). We assessed characteristics/outcomes of patients with PsA receiving tofacitinib monotherapy vs combination therapy with conventional synthetic disease-modifying antirheumatic drugs.</p><h3>Methods</h3><p>Claims data from Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart (OC) and Merative™ MarketScan<sup>®</sup> (MS) databases between December 2017 and February 2020 were analyzed. Outcomes assessed were adherence/persistence by therapy type (monotherapy/combination therapy); HCRU/costs (per patient per month) by periods on-treatment (sum time on tofacitinib) and off-treatment (sum time off tofacitinib [gap of > 60 days]) plus therapy type.</p><h3>Results</h3><p>This analysis included 274 and 395 tofacitinib-treated patients in OC (70.4% female, mean age 54.4 years) and MS (68.9% female, mean age 51.4 years), respectively. Percentages of patients with a proportion of days covered ≥ 0.8 at 12 months for monotherapy vs combination therapy were OC, 44.5% vs 53.8%; MS, 36.4% vs 45.7%. Generally similar trends were seen over 24 months and for medication possession ratio ≥ 0.8. Median (95% confidence interval) times to treatment discontinuation for monotherapy vs combination therapy were OC, 10.1 (7.4–11.8) vs 16.7 (8.3–26.6) months; MS, 6.9 (5.6–9.4) vs 11.0 (6.1–13.9) months. During off-treatment vs on-treatment periods, numerical decreases were observed for all-cause (OC, $5383 vs $6149; MS, $4145 vs $5180) and PsA-related costs (OC, $3237 vs $4515; MS, $2703 vs $3907) regardless of therapy type. During off-treatment vs on-treatment periods, numerical increases in outpatient visits for all-cause (OC, 2.37 vs 2.05; MS, 2.15 vs 1.99) and PsA-related visits (OC, 0.60 vs 0.46; MS, 0.47 vs 0.44) were observed, and PsA-related medications numerically decreased (OC, 1.21 vs 1.53; MS, 1.05 vs 1.48).</p><h3>Conclusion</h3><p>In this USA-based claims analysis, tofacitinib adherence was numerically lower for patients with PsA receiving monotherapy vs combination therapy. Costs numerically decreased off-treatment vs on-treatment, irrespective of therapy type, driven by lower medication costs.</p></div>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\"41 10\",\"pages\":\"3850 - 3867\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399223/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12325-024-02904-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02904-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
导言：据报道，银屑病关节炎（PsA）患者的功能障碍增加与医疗资源利用率（HCRU）和费用增加之间存在关联。我们评估了接受托法替尼单药治疗与传统合成改善病情抗风湿药联合治疗的 PsA 患者的特征/结果：分析了 Optum® Clinformatics® Data Mart (OC) 和 Merative™ MarketScan® (MS) 数据库中 2017 年 12 月至 2020 年 2 月期间的索赔数据。评估的结果包括按治疗类型（单一疗法/联合疗法）划分的依从性/持久性；按治疗期间（服用托法替尼的时间总和）和非治疗期间（停用托法替尼的时间总和[间隙>60天]）加治疗类型划分的HCRU/费用（每位患者每月）：该分析分别纳入了274例和395例接受过托法替尼治疗的OC（70.4%为女性，平均年龄54.4岁）和MS（68.9%为女性，平均年龄51.4岁）患者。12个月时，单一疗法与联合疗法覆盖天数比例≥0.8的患者比例分别为：OC，44.5% vs 53.8%；MS，36.4% vs 45.7%。在 24 个月内，药物持有率≥ 0.8 的趋势基本相似。单一疗法与联合疗法停药时间的中位数（95% 置信区间）分别为：OC，10.1（7.4-11.8）个月 vs 16.7（8.3-26.6）个月；MS，6.9（5.6-9.4）个月 vs 11.0（6.1-13.9）个月。在非治疗与治疗期间，观察到全因费用（OC，5383 美元 vs 6149 美元；MS，4145 美元 vs 5180 美元）和 PsA 相关费用（OC，3237 美元 vs 4515 美元；MS，2703 美元 vs 3907 美元）均有所下降，与治疗类型无关。在非治疗与治疗期间，观察到全因（OC，2.37 vs 2.05；MS，2.15 vs 1.99）和PsA相关门诊就诊人数增加（OC，0.60 vs 0.46；MS，0.47 vs 0.44），PsA相关药物治疗人数减少（OC，1.21 vs 1.53；MS，1.05 vs 1.48）：结论：在这项基于美国的索赔分析中，接受单一疗法与联合疗法的PsA患者对托法替尼的依从性较低。无论治疗类型如何，非治疗与治疗期间的费用在数字上都有所下降，原因是药物费用较低。
Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases
Introduction
Associations between increased functional disability and higher healthcare resource utilization (HCRU) and costs were reported in patients with psoriatic arthritis (PsA). We assessed characteristics/outcomes of patients with PsA receiving tofacitinib monotherapy vs combination therapy with conventional synthetic disease-modifying antirheumatic drugs.
Methods
Claims data from Optum® Clinformatics® Data Mart (OC) and Merative™ MarketScan® (MS) databases between December 2017 and February 2020 were analyzed. Outcomes assessed were adherence/persistence by therapy type (monotherapy/combination therapy); HCRU/costs (per patient per month) by periods on-treatment (sum time on tofacitinib) and off-treatment (sum time off tofacitinib [gap of > 60 days]) plus therapy type.
Results
This analysis included 274 and 395 tofacitinib-treated patients in OC (70.4% female, mean age 54.4 years) and MS (68.9% female, mean age 51.4 years), respectively. Percentages of patients with a proportion of days covered ≥ 0.8 at 12 months for monotherapy vs combination therapy were OC, 44.5% vs 53.8%; MS, 36.4% vs 45.7%. Generally similar trends were seen over 24 months and for medication possession ratio ≥ 0.8. Median (95% confidence interval) times to treatment discontinuation for monotherapy vs combination therapy were OC, 10.1 (7.4–11.8) vs 16.7 (8.3–26.6) months; MS, 6.9 (5.6–9.4) vs 11.0 (6.1–13.9) months. During off-treatment vs on-treatment periods, numerical decreases were observed for all-cause (OC, $5383 vs $6149; MS, $4145 vs $5180) and PsA-related costs (OC, $3237 vs $4515; MS, $2703 vs $3907) regardless of therapy type. During off-treatment vs on-treatment periods, numerical increases in outpatient visits for all-cause (OC, 2.37 vs 2.05; MS, 2.15 vs 1.99) and PsA-related visits (OC, 0.60 vs 0.46; MS, 0.47 vs 0.44) were observed, and PsA-related medications numerically decreased (OC, 1.21 vs 1.53; MS, 1.05 vs 1.48).
Conclusion
In this USA-based claims analysis, tofacitinib adherence was numerically lower for patients with PsA receiving monotherapy vs combination therapy. Costs numerically decreased off-treatment vs on-treatment, irrespective of therapy type, driven by lower medication costs.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
